Compare UK & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UK | CDT |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | China | United States |
| Employees | 42 | 4 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.4M |
| IPO Year | N/A | N/A |
| Metric | UK | CDT |
|---|---|---|
| Price | $2.05 | $2.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.2K | ★ 400.4K |
| Earning Date | 03-24-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.30 |
| 52 Week High | $5.90 | $11.00 |
| Indicator | UK | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 69.74 |
| Support Level | $1.92 | $2.66 |
| Resistance Level | $2.22 | $4.50 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.02 | 0.35 |
| Stochastic Oscillator | 28.57 | 74.58 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has two operating segments: Workspace membership, and Other services. The Workspace membership segment generates the majority of the company's revenue.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.